Novel half-sandwich ruthenium(II) complexes with aminomethyl(diphenyl)phosphine derived from fluoroloquinolones (RuPCp, RuPSf, RuPLm, RuPNr) were being investigated as alternatives to well-established metal-based chemotherapeutics. All compounds were characterized by elemental analysis, selected spectroscopic methods (i.e., absorption and fluorescence spectroscopies, ESI-MS, NMR, circular dichroizm), X-ray diffractometry, ICP-MS, and electrochemical techniques. To overcome low solubility, serious side effects connected with systemic cytotoxicity of ruthenium complexes, and acquiring the resistance of cancer cells, polymeric nanoformulations based on Pluronic P-123 micelles loaded with selected Ru(II) complexes were prepared and characterized. Resulting micelles (RuPCp_M, RuPNr_M) enabled efficient drug accumulation inside human lung adenocarcinoma (A549 tumor cell line), proved by confocal microscopy and ICP-MS analysis, allowing cytotoxic action. Studied complexes exhibited promising cytotoxicity in vitro with IC50 values significantly lower than the reference drug -cisplatin. The fluorescence spectroscopic data (CT-DNA titration, in vitro cell staining) together with analysis of DNA fragmentation (pBR322 plasmid, comet assay) provided clear evidence for the interaction with DNA inducing apoptotic cell death.
Introduction
Despite the medicine and pharmacology development, cancer diseases are still one of the most often causes of death in the world. Among many of organic and inorganic compounds considered as potential chemotherapeutic agents, it is supposed that the metal complexes are ones of the most promising group. Their therapeutic potential in cancer therapy has recently attracted a lot of interest mainly because of metals, in particular transition metals. They exhibit unique characteristics, such as redox activity, variable coordination modes and reactivity towards the organic substrates. For instance, the chemistry of ruthenium compounds has currently received intensive scrutiny, due to increasing interest in providing new alternatives to cisplatin. Ruthenium-based complexes have been developed not only because of promising cytotoxic anticancer properties but as well due to causing fewer and less severe side effects than the corresponding platinum(II) compounds.
The discovery of therapeutic activity of (ImH)[trans-RuCl 4 (DMSO) Im] (NAMI-A) and (IndH)[trans-RuCl 4 (Ind) 2 ] (KP1019) resulted in great interest in the field of ruthenium complexes possessing prospective cytotoxic activity, including organometallic ruthenium(II) compounds [1] [2] [3] [4] [5] . At present, two classes of half sandwich η 6 -arene-Ru (II) complexes are of the most interest: (i) the monofunctional compounds, represented by [(η 6 -cym)Ru(en)Cl]PF 6 (cym = 1-methyl-4-(1-methylethyl)benzene, en = 1,2-ethylenediamine) and (ii) the bifunctional, represented by [((η On the other hand, RAPTA-C exhibits low in vitro activity, while being active in vivo and inhibiting lung metastases in mice [6] .
Furthermore, combination of two or even more multifunctional structural elements brings into play different properties of a compound and may result in improving the spectrum of biological activity, novel mechanisms of action or modification of the pharmacokinetic profile of the drug [7, 8] . For instance, piano-stool Ru(II) compounds containing phosphines derived from fluoroquinolones can be prominent examples of this popular strategy of combining the structural elements, adopted currently in the design of new therapeutics. Quinolones are broadspectrum antibiotics used in human and veterinary medicine for treatment of bacterial infections. What is noteworthy, quinolones also proved to cause immunomodulation and antitumor effects by different possible mode of action e.g., inhibition of the activity of HERG -one of the potassium channels, which are important proteins involved in the process of cancer cell proliferation [9] . Notably, quinolones are nowadays subject of many structural modifications, including coordination compounds formation, aimed at not only defeat of increasing microbial resistance against antibiotics, but as well at potential alternatives to well-established anticancer chemotherapeutics.
In our group we are focused on synthesis and characterization of metal complexes with phosphanes -a very interesting class of ligands with great capacity to structural modifications and tuning their physicochemical and, in consequence, biological properties. The majority of ruthenium(II) aminomethylphosphanes' coordination compounds exhibited cytotoxicity in vitro against cancer cells close to cisplatin [10] . Moreover, the synthesized copper(I) and copper(II) complexes with phosphanes modified with quinolones (i.e., ciprofloxacin PCp, sparfloxacin PSf, lomefloxacin PLm, norfloxacin PNr) turned out to be more active than the parent antibiotics, and noteworthy possessed cytotoxicity in vitro towards selected cancer cell lines higher than cisplatin [11] [12] [13] [14] . These findings encouraged us to implement quinolones' phosphanes as well to half-sandwich ruthenium(II) complexes and investigate their prospective anticancer activity.
Herein, we present the synthesis, physicochemical characterization, and preliminary biological study on anticancer activity in vitro evaluated towards lung adenocarcinoma of four novel piano-stool ruthenium(II) complexes. These organometallic complexes are an extension of the mono(aminomethyl)phosphane complex (RuPP 1 ) reported recently [10] , in which N-ethylpiperazine ring was replaced by heterocyclic moieties of fluoroquinolones: ciprofloxacin (RuPCp), sparfloxacin (RuPSf), norfloxacin (RuPNr) or lomefloxacin (RuPLm) (Fig. 1) .
Effective uptake of metallodrugs, for instance ruthenium complexes, by cancer cells and normal cells is important factor for selective and effective cancer therapy. The high systemic cytotoxicity of chemotherapeutics, demonstrated by the uncontrolled destruction of normal cells, as well as the development of multidrug resistance, support the need to look for new effective targeted treatments based on nanotechnology and the changes in the molecular biology of the tumor cells. Thus, what is noteworthy, the main aim of this study was also to develop a new polymeric micellar formulation for effective ruthenium (II) complexes delivery, intended to be intravenously administered. To achieve this purpose, Pluronic P-123 (PEO 20 -PPO 70 -PEO 20 ) with longer hydrophobic blocks, was chosen mainly because of its commercial availability, biocompatibility and safety [15] . To the best of our knowledge, there are few reports on encapsulation of half-sandwich Ru (II) complexes into polymeric micelles [16] [17] [18] . The most advanced and innovative approach is presented by Su et al., who as the first proposed self-assembled polymer-based nanocarriers for delivery of ruthenium complexes for anticancer phototherapy. Photoresponsive Ru(II)-containing block copolymers release Ru(II) complex and 1 O 2 that both kill cancer cells [19] [20] [21] .
Materials and methods

Reagents
All starting materials, including a 2nd (HCp, HNr, HLm) and 3rd (HSf) generation fluoroquinolones (> 98%), [Ru(η 6 -p-cymene)Cl 2 ] 2 (1) (> 98%), and Pluronic P-123 (PEO 20 -PPO 70 -PEO 20 ) were purchased from Sigma Aldrich and used as received. All syntheses were performed using standard Schlenk techniques. All solvents were deaerated prior to use. All obtained ruthenium complexes were dried under vacuum and increased temperature (40°C). Aminomethyl(diphenyl)phosphines: PSf (PPh 2 CH 2 Sf), PCp (PPh 2 CH 2 Cp), PLm (PPh 2 CH 2 Lm), and PNr (PPh 2 CH 2 Nr) were synthesized according to literature procedure described by our group elsewhere [22] .
Structural characterization
Single crystals of RuPCp•CHCl 3 •0.5CH 3 CN, 2RuPSf•2CHCl 3 , RuPLm•2CHCl 3 and RuPNr•2CHCl 3 were collected on SuperNova diffractometer using graphite monochromatic Mo K α radiation at 121 K, 126 K, 119 K or 130 K, respectively. Data processing was undertaken with CrysAlisPRO [23] . The structures were solved using direct methods and for refinement the non-H atoms were treated anisotropically. The main calculations were performed with SHELXL [24] and figures were plotted with MERCURY [25] . The crystal data, experimental details and refinement results are summarized in Table S1 .
Crystallographic collected with Bruker MicrOTOF-Q II spectrometer with ESI ion source in the following conditions: nebulizer pressure: 0.4 bar, dry gas: 4.0 l/ min heated to 180°C. Data were recorded in the positive ion mode, while profile spectra were acquired in the mass range 50-3000 m/z; end plate offset −500 V; capillary voltage 4500 V; mass resolving power of the instrument -over 18,000. Mass calibration was done using the cluster method with a mixture of 10 mM sodium formate and isopropanol (1:1, v/v) before run. In order to measure spectra the compounds were dissolved in chloroform. , data/restraints/parameters: 10379/0/537, T = 130 K.
Synthesis and characterization of compounds
Electrochemical characterization
Cyclic voltammetry (CV) for 1 mM ruthenium(II) complexes was carried out on an electrochemical analyser (Bio-Logic, SP-150). Three-electrode glass cell with a working electrode -graphite disk electrode (2 mm diameter), a counter electrode -Pt wire, and a pseudoreference electrode -Ag wire (Ag/Ag 
Interactions with CT-DNA
The stock solution of calf thymus DNA (CT-DNA) was prepared in 50 mM PBS (pH = 7.4). The concentration of CT-DNA was determined by spectrophotometer using molar absorption coefficient 6600 M 
DNA strand break analysis
In order to check the ability of RuPCp, RuPSf, RuPLm and RuPNr to induce single-or double-strand breaks in DNA the gel electrophoresis with pBR322 plasmid was performed. Compounds concentrations were equal to 100, 80, 60 and 40 µM in DMF. After 1 h incubation time at 37°C, 20 µl reaction mixtures were mixed with 3 µl loading buffer (bromophenol blue in 30% glycerol) and loaded on 2% agarose gels (with EB) in TBE buffer (90 mM TRIS-borate, 20 mM EDTA, pH = 8.0). Electrophoresis was conducted at constant voltage (115 V), for 3 h. At the end gel was photographed and processed with Digital Imaging System (GelDocIt).
Preparation of micelles
In the round-bottom flask 0.25 g of Pluronic P-123 was dissolved in CHCl 3 in 60°C, under reflux for 15 min. 1 ml of 0.5 mg/ml ruthenium compound and 1 ml of CHCl 3 were added to hot solution and refluxed for 15 min. Solvent was slowly evaporated on rotary evaporator in 50°C and 500 mbar with speed rotation 270 rpm. Then, obtained thin film was dried under pressure reduced to 15 mbar for 15 min. Flask was transferred to sonication bath and 20 aliquots of 0.5 ml of PBS were added to film. Obtained solution was sonicated further for 15 min. Then 0.1 ml of the resulting solution was transferred to 0.9 ml of PBS in order to determine the size of the micelles. The rest of solution was centrifuged (5000 rpm, 15 min) and obtained residue was lyophilized. The supernatant was used to check the concentration of non-encapsulated ruthenium complex utilizing ICP-MS technique (Perkin Elmer ELAN 6100). Drug loading content (LC) and encapsulation efficiency (EE) were calculated using equations: Micelles morphology was investigated with application of transmission electron microscopy (FEI™ Tecnai G2 T20). Micelles were dropped in a carbon coated copper grid, dried at room temperature and stained with a negative staining agent (phosphotungstic acid). The size distribution was determined from the enlarged TEM micrographs, using ImageJ software, counting at least 200 particles in different images. The size was also examined by dynamic light scattering techniques (DLS, ZetaSizer Nano ZS, Malvern Instruments).
Cell line
A549 cell line (human lung adenocarcinoma, morphology: epithelial, ATCC: CCL-185) was cultured in Dulbecco's Modified Eagle's Medium (DMEM, Corning) with phenol red, supplemented with 10% fetal bovine serum (FBS) and with 1% streptomycin/penicillin. Cells were cultured at 37°C under a humidified atmosphere containing 5% CO 2 . Passages were carried out using a solution containing 0.05% trypsin and 0.5 mM EDTA. All experiments were performed on cells in the logarithmic phase of growth.
Cytotoxic assay
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was performed according the protocol described elsewhere [27] . In brief, 1 × 10 4 cells per well were seeded in 96-well flat bottom microtiter plate one day before and were incubated with the tested Pluronic P-123 micelles loaded with RuPCp or RuPNr complexes (RuPCp_M and RuPNr_M, respectively) at various range of concentrations (0.2-20 μM) for 24 h. After this, supernatants were pipetted out carefully and each well was washed with PBS. A further 24 h was allowed for the cells to recover in a drug-free medium. Afterwards, cell viability was examined and IC50 was calculated using the Hill equation (Origin 9.0) with regard to the untreated cells (control). Each compound concentration was tested in five replicates and repeated at least three times. Determined values of IC50 are given as mean + S.D. (Standard Deviation). As well, cells after treatment were intravital stained with two commercially available dyes -acridine orange (AO, 5 mg/mL) and propidium iodide (PI, 5 mg/mL). Cells were incubated with dyes for 20 min in standard conditions, then dyes were removed, cells were washed with PBS twice, and examined using a fluorescence inverted microscope (Olympus IC51, Japan) with an excitation filter 470/20 nm.
Cellular uptake
A549 cells at density of 2 × 10 6 cells/2 mL were seeded on 6-well plates and were incubated with RuPCp_M and RuPNr_M formulations (2 μM) for 4 or 24 h at standard conditions (37°C, 5% CO 2 ). Additional wells were incubated with medium alone as negative control. Then, compound solutions were removed, the cells were washed twice with PBS buffer and trypsinized. Measurement of the concentration of ruthenium ions was carried out using a mass spectrometer (ELAN 6100 Perkin Elmer) with an inductively coupled plasma (ICP-MS). The number of cells in each sample was counted manually and cells were centrifuged to obtain the whole cell pellet for analysis. For analysis cells were mineralized in 1 mL of 65% HNO 3 at 60°C for 1 h. The copper content under each conditions is expressed as μg/ml Ru per 10 6 cells.
The experiment was repeated at least 3 times and results are presented as mean value +S.D.
Confocal microscopy
Confocal laser scanning microscopy (CLSM Nikon) was applied to visualize the intracellular accumulation of selected Pluronic P-123 Ru (II) complex formulation (RuPCp_M). In brief, A549 cells at a density of 5 × 10 5 cells/mL were seeded on coverslips in 6-well plates and incubated for 24 h allowing proper adhesion. Then, the growth medium was replaced with a medium containing 2 μM RuPCp_M and incubated for 4 h at 37°C in a humidified atmosphere containing 5% CO 2 . After this time, the cells were washed twice with PBS buffer and fixed by treating firstly with 2.5% glutaraldehyde in PBS and secondly with an increasing concentration gradient of ethanol (20, 40, 60 , 80 and 99%). Samples were directly imaged under a Nikon A1 confocal laser scanning system (CM) attached to an inverted microscope Nikon Ti (Japan). A 1009 objective lens (Nikon Plan Apo VC/1.40 oil) was used. The samples were excited with diode lasers (405 and 488 nm). Fluorescence spectra were collected using a 32-channel spectral detector.
Comet assay
The level of DNA damage was determined by the electrophoresis of single cells in agarose gel as earlier described [13] . Briefly, the cell suspension was mixed with low melting point agarose, set on slides, lysed and neutralized in appropriate buffers. Electrophoresis was performed at 23 V (0.74 V/cm, 300 mA) for 30 min at 4°C. All stages of the experiment were carried out in the dark to eliminate any extra DNA damages. Prior to analysis the slides were stained with propidium iodide (2.5 µg/ml). The analysis of DNA damage was carried out with COMET PLUS 2.9 software (Comet Plus, Theta System GmbH, Germany). The percentage content of DNA in the comet's tail (%DNA) was determined from 100 random images of comets per slide. The analysis was done in three replicates.
Results and discussion
Structural characterization
The products of syntheses were recrystallized in order to obtain pure complexes. Their purity were confirmed using elemental analysis, while the single crystals were analysed by X-ray diffraction technique (Fig. 2 , SI, Table S1 ).
All obtained ruthenium complexes crystallized in P1 space group with one exception -RuPLm•2CHCl 3 , which crystalized in P c 2 / 1 space group. What is noteworthy, in the case of 2RuPSf·2CHCl 3 , both molecules of RuPSf in asymmetry unit adopt slightly different conformation (SI, Fig. S1 ), whereas, in the case of the other three complexes, there is only one molecule in the asymmetric unit. Coordination of phosphanes derived from fluoroquionolones did not cause significant changes in the ruthenium surrounding. Namely, only a slight increment in distance between Ru 2+ ion and centre of gravity of p-cymene ring (C g ) is observed (from 1.647 Å in parent dinuclear ruthenium(II) complex -1 [10, 28] , to about 1.707 Å -average distance for all complexes). Moreover, the length of RueCl bonds decreased insignificantly from 2.444 Å to 2.416 Å (average for all complexes). The angle CleRueC g is higher in complexes comparing to dimeric ruthenium substrate of 2.7°. Mentioned changes in ruthenium(II) ion surrounding are very close to observed in time of RuPP 1 formation [10] . This suggests that extension of piperazine ring with heterocyclic moiety of fluoroquionolones do not affect the Ru-phosphane coordination significantly.
The 31 P{ 1 H} NMR analysis, very useful method for preliminary determination of sample purity, was applied to verify if the product of synthesis is desired one (SI, Table S2 ). First of all, the signal of uncoordinated aminomethylphosphane is situated in the negative part of spectrum (PCp: −27.4 ppm; PSf: −35.9 ppm; PLm: −27.4 ppm; PNr: −27.5 ppm) and undergoes a downfield shift to the positive part of spectrum as a result of phosphane coordination (RuPCp: 27.0 ppm; RuPSf: 25.7 ppm; RuPLm 26.1 ppm; RuPNr: 26.9 ppm). Absence of other signals in spectrum confirms that coordination compound is the only one product of synthesis, free from phosphane derivatives (e.g., phosphane oxides). Secondly, 1 
S2-S5).
It is well-documented in literature, that replacement of the chloride by a DNA fragment in the coordination sphere of the metal results in formation a covalent bonds between them, what accounts for the cytotoxicity of organoruthenium species [29] [30] [31] . In the case of complexes with the general formula [(η 6 -arene)Ru(L)Cl 2 ] (L = ligand) aquation seems to be important step in cytotoxicity, producing the ruthenium active site in order to react with biomacromolecules i.e., proteins, DNA. The RuPCp, RuPSf, RuPLm, and RuPNr, similar to previously published RuPP 1 , in controlled condition hydrolyze very slowly [10] . Nevertheless, in cellular environment there is a plethora of electron-donating species and in such conditions the substitution of any ligand cannot be excluded. Furthermore, it is well-known that hydrolysis, that is suppressed extracellularly, due to the high chloride concentration (104 mM), it occurs inside the cell, in cytoplasm or the nucleus, where the chloride concentration is significantly lower [6] . Thus, presumably, the studied complexes will hydrolyze relatively very slowly inside tumor cells, reaching the equilibrium with an amount of the complex remaining non-hydrolyzed. Indeed, both hydrolyzed and non-hydrolyzed complexes are able to interact with DNA (directly or through its ligands, respectively), thereby causing significant alterations to DNA structure. Importantly, also the non-hydrolyzed forms of RuPCp, RuPSf, RuPLm and RuPNr are able to interact with DNA (through fluoroquinolones or arene), therefore presumably the hydrolysis may not be the crucial process in case of synthesized complexes.
Electrochemical characterization
The reactivity of metal-based drugs depends largely on their ligand environment and coordination geometry, which is also determined by the redox properties. The knowledge of metal-centered redox potentials can provide an essential information for the design of new complexes and a better understanding of the role of metallodrugs in biological applications. The electrochemical properties of ruthenium(II) complexes were investigated in order to assess and understand their potential role in cellular signaling through redox chemistry. Any disturbances of intracellular redox processes may significantly influences on a plethora of cellular processes such as right proliferation. This may, in turn, result in serious consequences including cell death [32] . Crystal structures of the complex molecules RuPCp, RuPNr, RuPLm, and RuPSf (30% probability ellipsoids). The solvents' molecules and some hydrogen atoms were omitted for clarity.
The redox properties of new Ru(II) complexes and the corresponding ligands alone were determined by cyclic voltammetry in dimethylformamide (DMF) solutions (1 mM) using 0.1 M tetrabutylammonium perchlorate (TBAP) as the supporting electrolyte in the selected potential window from −0.5 V to 1.2 V vs Ag/Ag + at a scan rate of 10 mV/s. The cyclic voltammetric responses obtained for all studied complexes with apparent oxidation peaks localized at ca. 0.6 V and 0.9 V vs Fc 0/+ are presented in Fig. 3 .
All the complexes displayed irreversible one-electron redox waves, which can be attributed to Ru(II) ion oxidation at ca. 0.6 V vs Fc 0/+ . The determined oxidation potentials for studied ruthenium(II) complexes, referring to Ru(II)/(III) redox process, are in agreement with literature data for other organometallic Ru(II) compounds [30, 33, 34] . Additional peaks, observed in cyclic voltammograms of studied complexes, can be safely associated with oxidation processes within ligand moiety on comparing with the electrochemical data of ligands alone (SI, Fig. S7 ). From the electrochemical data, it can be concluded that the present ligand systems in form of aminomethylophoshine derivatives of antibiotics do not stabilize the oxidation state of ruthenium(II) ion. This means, that the investigated complexes are not electrochemically stable, suggested by observed some instability of the oxidized ruthenium species at the electrode surface. However, it can be presumed that the electron transfer reactions take place without gross changes in the stereochemistry of the complexes, that can be monitored by UV-vis spectroscopy. In UV-vis spectra no significant changes were observed, indicating the formation of completely new chemical compounds, as only decrease in absorption was detected after electrochemical study (SI, Fig. S8 ). What is also noteworthy, monitored changes in UV-vis spectra during 24 h in DMF solvent did not revealed spectral changes implicating ligands exchange due to DMF coordination (SI, Fig. S9 ).
Thus, even though it is stated that Ru(II) arene "piano-stool" complexes are normally unable to change their +II oxidation state due to stabilization by the π-bonded arene ligands [35] , the studied organometallic complexes with aminomethyl(diphenyl)phosphanes of fluoroquinolones are prone to undergo electrochemical processes. Taking into consideration the potential values for oxidation of Ru(II) ion it can be supposed that investigated complexes can participate in redox chemistry inside cells, as the required redox potential window is estimated to be −0.4 to +0.8 V vs NHE [36] . This may result in strengthening the production of reactive oxygen species and in consequence lead to irreversible changes in cellular redox equilibrium, that end in cell death.
Interactions with CT-DNA
Knowing that DNA is a potential target for transition metal anticancer complexes [6, 37, 38] , we investigated the binding profiles of studied ruthenium(II) complexes to calf thymus DNA (CT-DNA) in order to provide insight into their mechanism of action. Fluorescence spectroscopy was used to study kinetics of interactions between CT-DNA and studied ruthenium(II) complexes. To achieve this, the fluorescence spectra of complexes in the absence and presence of CT-DNA at different concentrations were recorded. Stern-Volmer plots, obtained by titration of CT-DNA-EB system with Ru(II) complexes in molar ratios 1:1:1, 1:1:2, 1:1:5, 1:1:10 and 1:1:20 (CT-DNA:EB:Ru) after 1 h incubation time, are presented in Fig. 4 .
Upon addition of CT-DNA to ligands or the corresponding Ru(II) complexes, a considerable decrease in fluorescence was observed without significant changes in the wavelength of CT transition for complexes. Stern-Volmer plots for all of the phosphanes (PCp, PSf, (Fig. 4) . The strength of the ligands' and complexes' intercalation with CT-DNA, expressed by K sv values, is shown in Table 1 . Interestingly, in-depth analysis of Stern-Volmer plots leads to conclusion, that from the point of view of more efficient interactions with CT-DNA, the presence of the cyclopropane substituent in the antibiotic structure of coordinated phosphine ligand plays a crucial role. This conclusion is drawn based on K sv values, which are 1.34 × 10 3 M −1 and 6.32 × 10 2 M −1 for RuPCp and RuPNr, respectively. The same dependence of values was observed for the corresponding phosphines (Table 1) . Whereas, substituents in piperazine structure did not influence intercalation properties of studied half-sandwich Ru(II) complexes modified with phosphane derivatives of fluoroquinolones, as there are not significant difference in K sv values for PSf and PLm ligands, as well as for RuPSf and RuPLm complexes ( Table 1 , Fig. 1 ). Moreover, circular dichroism (CD) spectroscopy demonstrated that the investigated RuPCp, RuPSf, RuPLm, RuPNr complexes did not cause the conformational changes in CT-DNA structure. After CT-DNA titration by Ru(II) complexes no noticeable changes in CD spectra were observed (SI, Fig. S11 ), indicating binding to DNA by coordination or destruction its superhelical conformation, in similarity to the corresponding phosphanes (PCp, PSf, PLm, and PNr) [11] . These findings suggest intercalation or surface interaction involving π-stacking interactions between the complex and the DNA base pair.
pBR322 plasmid damage
In order to get more information on a direct DNA-metal interaction of studied ruthenium(II) complexes we decided to study the alteration of DNA structure by the electrophoretic mobility of different forms of DNA plasmid on agarose gels (Fig. 5) .
When pBR322 plasmid was incubated with increasing concentrations of RuPCp an increase of the relaxed open circular form of the plasmid (form II) was observed, that was found to correlate inversely with the amount of the supercoiled form (form I). This clearly indicates that since a direct conversion of the form I into the form II is taking place, thus the studied complexes are able to cause a single-strain plasmid cleavage. It can also be supposed that investigated complexes are not capable of a double-strain plasmid damage leading to formation of a linear form of the plasmid (form III), which is not observed in the gel electrophoresis of pBR322 plasmid (Fig. 5) . It is worth mentioning that the corresponding ligands alone (PCp, PSf, PLm, and PNr), even though they exhibited slight interactions with CT-DNA (vide supra, Fig. 4) , did not cause any DNA degradation [11] . Our findings are in agreement with work of Romerosa et al., who also observed formation of open circular form of plasmid resulting from not selective interactions of cyclopentadienidoruthenium(II) complexes bearing water-soluble phosphanes with nucleobases within intra-or inter-strand crosslinking. The authors suggested that piano-stool Ru(II) complexes can be active DNA agents acting by both mechanisms -with or without phosphine ligand dissociation (non-dissociative or dissociative mechanism, respectively) [29] . Fig. 5 . Selected agarose gel electrophoresis of pBR322 plasmid cleavage by half sandwich ruthenium(II) complex with aminomethylphosphines derived from ciprofloxacine in the 10% DMF solution. Lanes: 1 -plasmid (control); 2 -plasmid + 60 μM RuPCp; 3 -plasmid + 80 μM RuPCp; 4 -plasmid + 100 μM RuPCp.
Polymeric micelles
The emergence of selective and efficient delivery of highly hydrophobic drugs into living system has intensified the need for their encapsulation inside drug delivery systems, for instance polymeric micelles, liposomes, and other more sophisticated supramolecular assemblies [15, [39] [40] [41] [42] . The versatility of polymeric micelles produced from amphiphilic copolymers offers variety of self-assembled nanostructures with diverse morphology and size in the range between 10 and 200 nm [39] . This results in significant advances in biomedical area due to their varying functions and clinical applications. Furthermore, this strategy enables to reduce systemic toxicity by enhancing passive accumulation in the tumor tissue due to the enhanced permeability and retention (EPR) effect [43] [44] [45] .
Furthermore, since most of the ruthenium(II) complexes are not sufficiently soluble in water, therefore DMSO or DMF has to be usually used as solubilizing agent. However, this often leads to the solvolysis of the ruthenium(II) complexes, as shown recently for instance for [Ru(η 6 -arene)Cl 2 (L)] complexes (L = N-heterocyclic ligands) [46] . In consequence, solvolised ruthenium(II) complex may exhibit totally different activity in vitro in comparison to a parent dichlorido compound.
In the case of the half-sandwich ruthenium(II) complex RuPP 1 , studied by us previously and treated as the parent complex, we observed that this complex was susceptible to decomposition [10] . Thus, in order to avoid solvolysis of metal complexes various delivery systems such as mentioned above formulations loaded with these complexes have been currently proposed. Concluding, justification of application of drug delivery systems for highly active anticancer compounds lies not only in prevention of hydrolysis or solvolysis, but also in precise accumulation in the target tumor tissue, drug release, and selective local application [8] . Accordingly to all above-mentioned and due to poor solubility of studied ruthenium(II) complexes in water we decided to encapsulate two complexes (RuPCp and RuPNr) into polymeric micelles made of Pluronic P-123 (PEO-PPO-PEO triblock copolymer), using thin-film hydration method [47] . RuPCp and RuPNr were selected consciously because of differences in the structure of coordinated fluoroquinolones (cyclopropyl and ethyl moiety in quinolone, respectively). This presumably resulted in the strongest and the weakest interaction with CT-DNA for RuPCp and RuPNr, respectively (vide supra, Fig. 4) . Apparently, these complexes should also exhibit different biological activity in vitro. TEM images of selected Pluronic P-123 micelles with encapsulated RuPNr complex (RuPNr_M) with statistical analysis of size (ImageJ) are presented in Fig. 6 .
Negative staining TEM images revealed spherical shape and smooth surface forming homogeneous polymeric micelles with a size in agreement with DLS data (Table 2) . Drug loading content (LC) and encapsulation efficiency (EE) were assessed with application of ICP-MS technique ( Table 2 ). In the case of both studied complexes the determined LC and EE values prove effective and efficient loading of the Ru(II) complexes inside the Pluronic P-123 micelles, what will ensure their effective delivery. The mean micelle size of RuPCp_M and RuPNr_M was less than 50 nm, which is smaller than the critical size required to avoid capture by the reticuloendothelial system (RES). In view of the determined small size of the Pluronic P-123 micelles loaded with RuPCp or RuPNr complexes (ca. 25 nm), it is plausible that such nanoformulations will facilitate ruthenium(II) complexes accumulation into tumor tissues combining the avoidance of the RES system with the EPR effect and low steric hindrance. Zeta potential of stable RuPNr_M micelles was equal to be −1.59 ± 0.33 mV (pH = 7.4), resulting from slightly negative potential of uncharged PEO amphiphilic copolymers [48] . Given low value indicates the tendency to aggregation of synthesized micelles, what is beneficial for accelerating of drug release. As the polymeric micelles enter the tumor cells (vide infra, Figs. 8 and 9 ), it can be supposed that in pathological tumor microenvironment, characterized by lower pH (e.g., pH = 5.5 for endosome, pH = 5.0 for lysosome), when compared with normal tissues (pH = 7.4), efficient release of Ru(II) complexes will be facilitated. This will be realized mainly due to the fact that such Pluronic P-123 nanoformulations tend to form aggregates releasing their load in dependence to pH, as observed also by other authors [47] .
Cytotoxicity study in vitro
Herein, the cytotoxicity of two particular polymeric formulations RuPCp_M and RuPNr_M was studied on selected cell line -a lung adenocarcinoma cells (A549 cell line). The cell viability was assessed by MTT assay after 24 h incubation with studied formulations and Fig. 6 . TEM images of Pluronic P-123 formulation with encapsulated RuPNr complex (RuPNr_M) with statistical analysis of size (ImageJ). additional 24 h for recovery time in a formulation-free media ( Table 3) .
As shown in Table 3 , both RuPCp_M and RuPNr_M exhibited high cytotoxicity towards studied human cancer cells, when compared with the earlier studied by our group organometallic ruthenium(II) complexes with aminomethylphospanes derived from morpholine or piperazine and not bearing fluoroquinolones' moieties. What is noteworthy, the determined IC50 values are one order of magnitude lower than in the case of the latter complexes and cisplatin [10] . Notably, RuPCp_M displayed higher cytotoxicity than RuPNr_M in vitro, what corresponds to their higher affinity of the DNA-binding showed in the model study on CT-DNA interactions (vide supra, Fig. 4 ).
Cellular morphology after treatment with studied micelles was visualized via microscopy, including fluorescent imaging after adequate dye staining with acridine orange (AO) and propidium iodide (PI) (Fig. 7) .
AO is a vital dye, which stains both live and dead cells, while PI stains only cells that have lost membrane integrity. Analysis of fluorescence images revealed significant changes in cell morphology, indicating number of viable (green, AO+) and dead (red, PI+) cells. While, untreated control cells appeared uniformly green with spindleshape.
Cellular uptake
One of the major goals in the development of novel metal-based anticancer drug candidates is to obtain an efficient uptake of a compound into tumor cells, while presenting increased therapeutic efficacy and decreased cytotoxicity in the case of healthy tissue. Confocal microscopy was applied to confirm cellular uptake of studied RuPCp_M and RuPNr_M formulations (Fig. 8) .
Confocal microscopy confirms unquestionably cellular uptake of RuPCp_M and RuPNr_M formulations. This is proved by analysis of the cross-sectional images and emission spectra of the tested compounds, that penetrated into the cells. Non-differing in intensity emission from the compounds was visible inside the whole cell, what indicates their uniform distribution throughout the cells and no favorable accumulation in any cellular compartments or organelles.
Furthermore, to assess how efficiently micelles loaded with ruthenium(II) compounds were taken up by A549 cells, the cellular accumulation of Ru ion was detected using ICP-MS technique after cell treatment with 2 μM RuPCp_M or RuPNr_M for 4 and 24 h (Fig. 9) .
Time-depending cellular uptake of RuPCp_M and RuPNr_M was determined to be 0.77 ± 0.21 μg/ml Ru/10 6 cells and 0.72 ± 0.17 μg/ml Ru/10 6 cells, respectively following long-term treatment (24 h ). This indicates significantly increased accumulation of Ru(II) complexes, when compared with studied previously counterparts with aminomethylphospanes derived from piperazine not bearing fluoroquinolone's motif, as reported previously [10] . These results, together with confocal analysis, clearly support an enhanced pattern of cellular uptake into A549 cells of micellar nanocarriers containing the studied organometallic ruthenium(II) complexes. It can be concluded that successful and efficient uptake of poorly soluble half-sandwich Ru(II) complexes is observed mainly because of the interesting feature of Pluronic P-123, which is capable to interact with cell membranes, leading to decreased microviscosity, pore formation on the membrane and accelerated transmembrane drug translocation [47] .
Comet assay
Several mechanisms have been proposed to elucidate the anticancer activities of ruthenium complexes: (i) interaction with DNA, (ii) blocking of the cell cycle, (iii) inhibition of various kinases, (iv) inhibition of topoisomerases, and (v) induction of mitochondrial dysfunction pathway [1] . To gain more insight into the underlying mechanism of cytotoxicity induced by a nanoformulation containing selected Ru(II) complex (RuPCp_M), induction of DNA damage, which is considered as hallmark of apoptosis, was investigated. The single-cell gel electrophoresis (comet assay) is an effective and simple measure for evaluating the DNA integrity, since a cell with damaged DNA stained with EB, subjected to electrophoresis, appears as a comet like.
As shown in Fig. 10 in the control (untreated cells), the percentage of DNA in the comet tail was found to be at ca. 8%. After the treatment of A549 cells with the increasing concentration of RuPCp complex for 24 h (introduced into cells in form of RuPCp_M formulation), the statistically significant and well-formed comets like were observed. The length of tail indicated the extent of ca. 26% of DNA damage. These results identify the studied complex can lead to DNA damage in A549 cells, which is an undoubted hallmark of apoptotic cell death, mitotic catastrophe or both [49] . Importantly, based on these findings along with, in particular, interactions with CT-DNA and pBR322 plasmid (intercalating properties, cleavage of DNA helix, respectively), it can be supposed that studied arene Ru(II) complexes arrest cells for DNA repair resulting in irreversible DNA damage and subsequent cell death. It is well-known that DNA damage can be caused not only by direct interactions of chemotherapeutics with nucleic acid double helix but also by other mechanisms such as ROS-mediated DNA cleavage. First of all, our research shows that the mechanism associated with the generation of ROS cannot be rejected. In addition, other molecular pathways affecting the increase of DNA damage such as mitochondrial activation of apoptosis should also be taken into account. Thus, more precise investigation focused on elucidation of molecular mode of action of studied piano-stool ruthenium(II) complexes with phosphane derivatives of fluoroquinolones is required. 
Conclusions
In this paper, we explored the potential of Pluronic P-123 micelles as suitable nanocarriers to deliver two selected ruthenium(II) compounds RuPCp and RuPNr, allowing to maintain their activity and mechanism of action. Studied functionalities such as micelle stability, micellar size distribution, drug loading capacity, and high cytotoxic index towards cancer cells provide with possible application of these polymeric nanosystems for selective and efficient delivery of anticancer drugs i.e., organometallic Ru(II) complexes with phosphine derivatives of fluoroquinolones. What is noteworthy, determined small size of prepared micelles (ca. 25 nm) and high drug loading efficiency (ca. 95%) ideally meets crucial design criteria for an effective penetration into the tissue (proved by confocal microscopy). Presumably, this will provide stealth against mononuclear phagocyte system (MPS) for sufficient longer circulation and better accumulation in the target tissue. Importantly, based on electrochemical characterization of all studied complexes we postulate their participation in intracellular redox processes connected with ROS generation. Furthermore, study on interactions with macromolecules (CT-DNA, pBR322 plasmid) revealed: (i) intercalating properties of investigated arene Ru(II) complexes, and (ii) possibility to induce a single strand DNA cleavage. Irreversible DNA fragmentation was also confirmed by single cell gel electrophoresis (comet assay) in an agarose gel matrix. In light of these results it may be supposed that prepared FDA-proved polymeric nanoformulations containing arene Ru(II) complexes with aminomethyl(diphenyl)phosphine derived from fluoroloquinolones will assure safe biodegradability for easy elimination from the body, targetability for therapeutic efficacy, tunable stability, improved pharmacokinetics and pharmacodynamic profiles. Finally, reproducibility along with facile and inexpensive method of synthesis will be also guaranteed. 
